Bristol Myers Squibb Unleashes 'SuperDuperPOD' AI Power to Revolutionize Drug Discovery
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Pharmaceutical giant Bristol Myers Squibb (BMS) just announced a massive leap in its drug discovery efforts, deploying a second, even more powerful NVIDIA DGX SuperPOD. Nicknamed the 'SuperDuperPOD,' this advanced computing cluster, built on the cutting-edge Vera Rubin architecture, is designed to give every single BMS scientist, no matter their technical skill, direct access to the fastest AI tools for finding new medicines. The move effectively doubles BMS high-performance computing power, promising to accelerate the search for new treatments across tough diseases like cancer and heart conditions. This isn't just about faster computers; it's a strategic shift. BMS has already seen huge wins from its first SuperPOD over the past three years, cutting weeks off manual tasks like identifying potential drug targets and expanding its library of special 'CELMoD compounds' that fight diseases like blood cancer. The company's 'Predict First' strategy, where AI guides drug design even before lab experiments begin, is now a core part of its work, influencing most of its drug programs. This push for 'hybrid intelligence' – where human scientists work hand-in-hand with AI co-scientists – places BMS firmly in a heated race among pharmaceutical leaders, including rivals like Eli Lilly and Roche, who are also investing heavily in similar AI supercomputers. The new SuperPOD, featuring NVIDIA Vera CPUs and Rubin GPUs, boasts up to ten times greater performance per megawatt than older systems, making it incredibly powerful yet energy-efficient. BMS plans to combine both its SuperPODs into one global system, managed by NVIDIA Mission Control, allowing researchers worldwide to run complex predictions using simple language. This means quicker experiments, exploration of a much wider range of chemical possibilities, and a future where scientists can focus on breakthrough ideas instead of managing complex tech, ultimately speeding up the delivery of life-changing medicines to patients.